Trevi Therapeutics Inc.
Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer
About Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.
/ 
Others were interested in
See all stocksFrequently asked questions
To buy Trevi Therapeutics Inc. stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Trevi Therapeutics Inc. by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Trevi Therapeutics Inc. is TRVI:xnas. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Trevi Therapeutics Inc. has its primary listing on NASDAQ. You can trade Trevi Therapeutics Inc. with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Trevi Therapeutics Inc. is available to trade on SaxoInvestor and SaxoTraderGO. You can buy shares directly and include Trevi Therapeutics Inc. as part of a broader investment portfolio. Explore our SaxoInvestor platform.
Learn more about investing and trading at Saxo’s educational content hub. Explore portfolio strategies, types of stocks, diversification, and valuation measures— so you can make more informed decisions when considering shares like Trevi Therapeutics Inc..